

NICE METHODS REVIEW SPECIAL

Members Bulletin - 30th July 2020

Dear All,

I hope you are all well.

And an e-bulletin which does not focus on COVID-19 but instead one that looks at the very important topic of NICE and its methods review.

Essentially we want (as ever!) to ensure that the voice of rare and less common cancers is heard in this complex piece of work and have been more than ably led on this by our more informed member charities of whom there are many.

So where we are now is that below are:

- A [briefing doc](#) for members who are less familiar with NICE than others;
- A [response](#) to the review Priorities for the *NICE Review of Methods for Health Technology Evaluation Programmes* relating to the rare and less common cancer community;
- And a [letter to Dame Gillian Leng](#) outlining the significant concerns from the patient community that lie outside of the scope of this review.

What we would like members to do is:

- To give us a more demonstrably powerful voice on this is to **sign up** to the recommendations on behalf of your organisation – both the response and the review;
- If you are happy to do so please reply to [Elisa](#) by email with the subject line *Signing up to the Cancer52 NICE Methods Review response and letter*;
- And attach a logo, name and job title of signatory;
- By Friday 14th August 2020.

Our huge thanks to:

- **Charlotte Martin** of Leukaemia Care who has led on this work and fellow travellers **Zack Pemberton-Whiteley**, also of Leukaemia Care and **Bradley Price** of Sarcoma UK. Other charities who joined our workshop we held in March (face to face pre-COVID-19) included **Becky Rice** - Pancreatic Cancer Action; **Dave Ryner** - Chronic Myeloid Leukaemia Support; **Debra Montague**, ALK Positive; **Jane Lyons**, Cancer52 (*Co-Chair*); **Jen Mitchell**, Cancer52 Policy Adviser; **Nic Puntis**, GIST Support UK; **Nikie Jervis**, Neuroendocrine Cancer UK; **Phil Reynolds**, Blood Cancer UK; **Sharon Deveson Kell**, Kidney Cancer Support Network; and **Susanna Smith**, Kidney Cancer UK;
- **Janssen**, a pharmaceutical company of Johnson & Johnson, with support from **M&F Health**, a communications consultancy. The roundtable meeting in March was hosted by Cancer52 and sponsored by Janssen, a pharmaceutical

company of Johnson & Johnson, with support from M&F Health, a communications consultancy. All materials have been developed by Cancer52 with support from M&F Health. Janssen had no editorial control of content.

With very best wishes and thanks,

Jane Lyons
CEO
Cancer52



www.cancer52.org.uk

Want to change how you receive these emails?
You can [update your preferences](#) or [unsubscribe from this list](#).

Copyright © Cancer52 All rights reserved.